Navigation Links
Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings
Date:10/13/2009

WALTHAM, Mass., Oct. 13 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month. The Company will also exhibit at the American Dietetic Association's (ADA) Food and Nutrition Conference & Expo in Denver, Colo.

Specific presentation details are as follows:

IDF 20th World Diabetes Congress - Montreal, Canada.

Date: October 20, 2009

Time: 1-2 p.m.

Interleukin Genetics will present a poster titled, "Perilipin, IL-1, ADRB and MCR-4 Gene Variants Identify Bariatric Surgery Patients who are Predisposed to Dyslipidemia," at the poster discussion session entitled Complications-dyslipidemia. The poster, #D-0809, will highlight findings that suggest genetic polymorphisms in the perilipin, IL-1, ADRB and MCR-4 genes may predispose to abnormal levels of blood lipids and therefore could have clinical utility in the management of obese patients.

American Society of Human Genetics 59th Annual Meeting - Honolulu, HI

Date: October, 21, 2009

Time: 1-2 p.m.

Interleukin Genetics will present a poster titled, "A Polymorphism in the IL1-B Gene is Associated with Vertebral Fracture Independent of Bone Mineral Density." The poster, #369, will highlight findings that suggest variations in the IL1B, VDR, and ESR1 genes may indicate susceptibility for vertebral fracture or low bone mineral density. These findings should be valuable in guiding medical management of osteoporosis, design of clinical trials of investigational new drugs, as well as guiding preventive treatments for individuals at risk for the disease.

Obesity Society 27th Annual Scientific Meeting - Washington, D.C.

Date: October, 25, 2009

Time: 1-7:30 p.m.

Interleukin Genetics will present a poster titled, "Perilipin, IL-1 and ADRB Gene Variants Identify Bariatric Surgery Patients who are Resistant to Weight Loss under Calorie Restriction in Preoperative Weight Loss Program." The poster, #322-P, highlights findings which suggest that genetic polymorphisms in perilipin, IL-1 and ADRB genes show strong association with resistance to weight loss under caloric restriction. These genetic risk markers could have important clinical utility in the medical management of obese patients and in the design of optimal weight loss programs.

In addition to the scientific presentations, Interleukin Genetics will exhibit at the following conference.

American Dietetic Association FNCE Meeting - Denver, CO

Date: October 17-20, 2009

Booth #1900

Interleukin Genetics will exhibit at the ADA's annual Food and Nutrition Conference & Expo, which will demonstrate the latest nutrition science information and foodservice trends. Highlighted at the Company's Booth will be the new Inherent Health((TM)) Weight Management Genetic Test designed to guide optimal diet and exercise regimens based on genetics.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests under the Inherent Health(TM) brand that empower consumers to prevent chronic diseases of aging, and provides genetic biomarker expertise to assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.

SOURCE Interleukin Genetics, Inc.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Announces Strategic Divestment of Alan James Group
2. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
3. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
4. Interleukin Genetics Reports First Quarter 2009 Financial Results
5. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
6. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
7. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
8. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
9. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
10. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
11. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: